Maravai LifeSciences announced the acquisition of assets and intellectual property from Molecular Assemblies. This strategic move is set to expand TriLink's capabilities in DNA production and long oligos, supporting next-generation nucleic acid therapies.
The acquisition is considered a vertical integration play, with the aim of utilizing internal inputs to achieve cost of goods benefits. The integration process is reportedly ahead of schedule, with the production of oligos over 200 bases already initiated.
Molecular Assemblies' aqueous enzymatic DNA synthesis platform is expected to enhance Maravai's ability to support nucleic acid-based therapies. This technology offers a smaller environmental footprint compared to traditional petrochemical-based DNA synthesis methods.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.